PolitiKit

Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.

Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries.

Innovation, Science and Economic Development Canada policies related to research and development for treatments for rare disorders.

Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.

Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases.

Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.

Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients

Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.

Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.

Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients

Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries.

Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.

Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases.

Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries.

Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients

Innovation, Science and Economic Development Canada policies related to research and development for treatments for rare disorders.

Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases.

Innovation, Science and Economic Development Canada policies related to research and development for treatments for rare disorders.

Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries.

Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.

Issues related to U.S. pharmaceutical importation, trade and policies, including research and development, regulatory authorizations, funding of medicines, supply sources and supply chains.

Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.

Federally-funded public drug plans, with respect to reimbursement for medicines for federal plan beneficiaries.

Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.

Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases.

Discussions on the renewal of the National Immunization Strategy to bolster public vaccination programs across Canada.

Discussions on strengthening Canada’s adult immunization programs, as access to adult vaccines remains inconsistent, inequitable and underfunded throughout the country.

Discussions on the renewal of the National Immunization Strategy to bolster public vaccination programs across Canada.

Discussions on strengthening Canada’s adult immunization programs, as access to adult vaccines remains inconsistent, inequitable and underfunded throughout the country.

Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with the Canadian Agency for Drugs and Technologies in Health (CADTH), Canada's Drug Agency and/or other pan-Canadian health organizations.

Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases.

nnovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda, the Biomanufacturing and Life Sciences Strategy and other government policies and programs related to incentivizing research and development activities in Canada.

Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board.

Bill C-64: An Act respecting pharmacare, with a particular focus on access to medicines and rare disease and orphan drug policies

Federally-funded public drug plans, with respect to reimbursement for drug products for federal plan beneficiaries.